Biography
<< Back
Kevin T. Conroy
Independent Director; Chair of the Compensation and Human Capital Committee
Elected
| Experience: | |
| 2009 - 2026 | CEO and Chairman of the Board (2014), Exact Sciences Corp. |
| (molecular diagnostics company) | |
| 2005 - 2008 | President and CEO, Third Wave Technologies, Inc. |
| (molecular diagnostics company) | |
| 2004 - 2005 | General Counsel, Third Wave Technologies, Inc. |
| (molecular diagnostics company) | |
| Prior | Various Leadership Positions at GE Healthcare |
| (medical technology company) |
Other Board Positions
Abbott Laboratories (2026 – present)
Exact Sciences Corp. (2014 – 2026)
Fuze Health (2025 – present)
Adaptive Biotechnologies Corporation (2019-2023)
Epizyme, Inc. (2017-2022)
CM Life Sciences II Inc. (2021)
SomaLogic, Inc. (2021)
Arya Sciences Acquisition Corp. (2018-2020)
Notable Experience and Key Board Contributions
- Mr. Conroy has extensive experience creating stockholder value as a business, legal, corporate strategy, and executive leader and has significant experience in the healthcare and the molecular diagnostics industries.
- At Exact Sciences, Mr. Conroy developed Cologuard and the company grew to $2.76B in revenue while serving 4.5 million patients.
- At Third Wave, Mr. Conroy developed and brought a novel cervical cancer screening test, Cervista, to patients.
Education
B.S. in Electrical Engineering from Michigan State University
J.D. from the University of Michigan Law School